12:00 AM
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Anoro Ellipta umeclidinium bromide/vilanterol regulatory update

FDA approved an NDA from GlaxoSmithKline for Anoro Ellipta umeclidinium bromide/vilanterol for long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). GSK said it is the first once-daily product approved in the U.S. that combines 2 long-acting bronchodilators for COPD. Anoro Ellipta is a fixed-dose inhaled dry powder...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >